DS
PACB icon

David Shaw’s Pacific Biosciences PACB Stock Holding History

David Shaw’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-52,000
Closed -$1.82M – 5151
2021
Q2 		$1.82M Buy
+52,000
New +$1.51M ﹤0.01% 3035

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's PACB Position: Q2 2026 in Review

David Shaw increased its Pacific Biosciences (PACB) stake by 16% in Q2 2026, buying an estimated $830K and bringing the position to 4,208,146 shares worth $7.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

David Shaw first reported a position in PACB in Q2 2013 and has held it in 46 quarters since. The position peaked at $39.5M in Q3 2021. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • David Shaw held 4,208,146 shares of Pacific Biosciences worth $7.07M as of Q2 2026.
  • David Shaw bought 570,599 Pacific Biosciences shares in Q2 2026, an estimated $830K.
  • Pacific Biosciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2132 holding.
  • David Shaw first reported a position in Pacific Biosciences in Q2 2013 and has held it in 46 quarters since.
  • David Shaw's Pacific Biosciences position peaked at $39.5M in Q3 2021.
  • 222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.